Zhilun Li Selected Research

1- (2- (1- (2- aminopyrimidin- 4- yl)- 2- ((2- methoxyethyl)amino)- 1H- 1,3- benzodiazol- 6- yl)ethynyl)cyclohexan- 1- ol

12/2015

p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhilun Li Research Topics

Disease

4	Neoplasms (Cancer) 12/2015 - 07/2010
2	Breast Neoplasms (Breast Cancer) 12/2015 - 09/2002
1	Crohn Disease (Crohn's Disease) 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2012
1	Ovarian Neoplasms (Ovarian Cancer) 10/2010
1	Carcinoma (Carcinomatosis) 09/2002

Drug/Important Bio-Agent (IBA)

2	p21-Activated KinasesIBA 12/2015 - 10/2010
2	IntegrinsIBA 01/2012 - 09/2002
2	integrin alphaVbeta5IBA 07/2010 - 09/2002
1	Ustekinumab (CNTO 1275)FDA Link 01/2021
1	1- (2- (1- (2- aminopyrimidin- 4- yl)- 2- ((2- methoxyethyl)amino)- 1H- 1,3- benzodiazol- 6- yl)ethynyl)cyclohexan- 1- olIBA 12/2015
1	Estrogen Receptor alphaIBA 12/2015
1	Tamoxifen FDA LinkGeneric 12/2015
1	Proteins (Proteins, Gene)FDA Link 01/2012
1	ErbB Receptors (EGF Receptor)IBA 10/2010
1	Phosphotransferases (Kinase)IBA 10/2010
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 10/2010
1	Cyclin D1IBA 10/2010
1	VitronectinIBA 09/2002
1	Integrin alphaVIBA 09/2002

Therapy/Procedure

1	Therapeutics 10/2010